The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2022 | Benefits of alnuctamab in the treatment of R/R multiple myeloma
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, outlines the advantages of the alnuctamab (formerly CC-93269), a novel BCMAxCD3 bispecific antibody, in the treatment of patients with relapsed/refractory (R/R) disease. Dr Cerchione explains that this agent is administered subcutaneously and has been shown to be very tolerable. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
